Further phase III trials are currently being conducted in earlier therapy timelines for prostate cancer for both [177Lu]Lu-PSMA-617, PSMAfore trial (NCT04689828) and the PSMAddition trial (NCT04720157), and [177Lu]Lu-PSMA I&T, SPLASH (NCT04647526) and ECLIPSE (NCT05204927). This evidence concerns the gene FOLH1 and prostate carcinoma.